 | • レポートコード：MRC2303I0172 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、132ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、2021年に1,588.89百万ドルであった世界のT細胞リンパ腫市場規模が、2027年には2,701.45百万ドルまで年平均8.25%で成長すると予測しています。本書では、T細胞リンパ腫の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、リンパ腫種類別（末梢性T細胞リンパ腫、皮膚T細胞リンパ腫、未分化大細胞型リンパ腫、血管免疫芽球性T細胞リンパ腫、T細胞性リンパ芽球性リンパ腫）分析、治療種類別（放射線治療、化学療法、免疫療法、幹細胞移植、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Mundipharma International、Bristol-Myers Squibb Company、Genmab AS、Johnson & Johnson （Janssen Pharmaceuticals Inc.）、Merck & Co. Inc.、F. Hoffmann-La Roche Ltd、Novartis AG、Autolus Therapeutics PLC、Acrotech Biopharma、Macopharmaなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のT細胞リンパ腫市場規模：リンパ腫種類別 - 末梢性T細胞リンパ腫の市場規模 - 皮膚T細胞リンパ腫の市場規模 - 未分化大細胞型リンパ腫の市場規模 - 血管免疫芽球性T細胞リンパ腫の市場規模 - T細胞性リンパ芽球性リンパ腫の市場規模 ・世界のT細胞リンパ腫市場規模：治療種類別 - 放射線治療の市場規模 - 化学療法の市場規模 - 免疫療法の市場規模 - 幹細胞移植の市場規模 - その他の市場規模 ・世界のT細胞リンパ腫市場規模：地域別 - 北米のT細胞リンパ腫市場規模 アメリカのT細胞リンパ腫市場規模 カナダのT細胞リンパ腫市場規模 メキシコのT細胞リンパ腫市場規模 … - ヨーロッパのT細胞リンパ腫市場規模 ドイツのT細胞リンパ腫市場規模 イギリスのT細胞リンパ腫市場規模 フランスのT細胞リンパ腫市場規模 … - アジア太平洋のT細胞リンパ腫市場規模 中国のT細胞リンパ腫市場規模 インドのT細胞リンパ腫市場規模 日本のT細胞リンパ腫市場規模 … - 中東・アフリカのT細胞リンパ腫市場規模 GCC諸国のT細胞リンパ腫市場規模 南アフリカのT細胞リンパ腫市場規模 … - 南米のT細胞リンパ腫市場規模 ブラジルのT細胞リンパ腫市場規模 アルゼンチンのT細胞リンパ腫市場規模 … - その他地域のT細胞リンパ腫市場規模 ・競争状況 ・市場機会・将来の動向 |
The T-cell lymphoma market was valued at USD 1,588.89 million in 2021, and it is expected to reach USD 2,701.45 million by 2027, registering a CAGR of 8.25% during the forecast period (2022-2027).
Due to the high transmission rate of COVID-19 and lack of treatment, many countries suffered, and they continue to bear a significant burden on their economies and healthcare systems. The COVID-19 outbreak may put patients with cutaneous lymphomas at additional risk of not receiving the necessary diagnostic procedures and treatment because they cannot access hospitals easily or due to healthcare resources limitations. Several guidelines for managing cutaneous lymphoma have been recently published to help dermatologists choose the right approach in the COVID-19 pandemic. However, these guidelines happen to be not applicable in countries that are still under a lockdown or do not have enough resources to implement the plan.
Moreover, the outbreak of COVID-19 impacted the cancer T-cell lymphoma market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced globally. The COVID-19 pandemic also affected the global economy and showed a huge impact on the general hospital care functioning for non-COVID-19 patients in hospitals across the world.
The growth of the T-cell lymphoma market is attributed to the rise in lymphoma cancer incidence due to radiations, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.
According to Leukemia & Lymphoma Society 2021, 186,400 people in the United States were diagnosed with leukemia and lymphoma in 2021. In addition, 825,651 people lived with lymphoma in the United States, 152,671 people lived with Hodgkin lymphoma, and 672,980 people lived with non-Hodgkin lymphoma. T-cell lymphoma is significantly contributing to non-Hodgkin lymphoma, which further boosts the overall market growth.
In addition, the growing uptake of premium-priced products such as Keytruda, Opdivo, and immune checkpoint inhibitors and the launch of several novel therapies with label extension of commercialized products are also boosting the overall market growth. However, the high cost associated with T-cell lymphoma treatment and the adverse side effects of therapies have been obstructing the overall market growth.
T-Cell Lymphoma Market Trends
Chemotherapy is Expected to Hold Significant Market Share over the Forecast Period
Chemotherapy is a type of drug treatment often used to treat lymphoma. It works by stopping and slowing down the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a particular area, but chemotherapy works throughout the whole body. This means that chemotherapy can destroy and damage cancer cells that have spread to other parts of the body away from the original tumor.
According to the European Society for Medical Oncology, the COVID-pandemic had generated a huge backlog in oncology care and research. In addition, cancer care was hit by the COVID-19 pandemic due to the halt in diagnostic procedures and surgical procedures. Moreover, as per many studies, cancer patients are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by the malignancy and anticancer treatment.
For instance, as per the American Society of Clinical Oncology, chemotherapy treatments and follow-ups were postponed during the COVID-19 pandemic. Even private clinics in major Indian cities reported a nearly 50% decrease in patients for cancer care. Overall cancer services declined by 50% in April and May 2020. As per a study titled ‘Impact of nationwide lockdown on cancer care during COVID-19 pandemic: A retrospective analysis from western India’ published in 2021, Chemotherapy was the most commonly received treatment (before lockdown 71.8% and during lockdown 45.9%).
Chemotherapy is used with surgery or radiation therapy, or both. In some cases, it is used in combination with other drugs, such as hormone therapy, targeted therapy, or immunotherapy. For example, chemo may be used to shrink a tumor before surgery or radiation therapy. Chemo used in this way is called neoadjuvant therapy or after surgery or radiation therapy to help kill any remaining cancer cells in the body. Chemo used in this way is called adjuvant therapy.
There are several types of chemotherapies given to T-cell lymphoma patients, including alkylating agents, plant alkaloids, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, and miscellaneous antineoplastics.
Favorable reimbursement policies concerning these drugs, making them accessible and affordable, are expected to positively impact the market studied. For instance, Pralatrexate, a chemotherapy drug used to treat patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), is listed under the PBS scheme by the Australian government.
Thus, with the rising awareness about the benefits of chemotherapy and favorable government policies, the market studied is expected to flourish during the forecast period.
North America Dominates the Market, and it is Expected to do the Same over the Forecast Period
Some of the factors driving market growth in the North American region include the high prevalence of T-cell lymphoma, the presence of key market players, and increasing research and development activities.
The COVID-19 outbreak impacted the cancer T-cell lymphoma market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced in the North American region. Some biopharmaceutical companies, such as Merck & Co. Inc. and Eli Lilly and Company, announced clinical trial delays. For instance, the data from ClinicalTrials.gov showed that more than 200 interventional oncology studies were suspended in March and April 2020 as a result of the COVID-19 crisis. In addition, 60% of institutions in the United States are enrolling new patients at a lower rate.
According to the Globocan 2020 report, Canada had 8,506 cases of Non-Hodgkin lymphoma and 313 deaths caused due to it in 2020. This is expected to increase T-cell lymphoma incidence in the country. The increase in cases of Non-Hodgkin lymphoma is expected to boost the demand for treatment options, which is going to positively aid market development, as T-cell lymphomas are a type of Non-Hodgkin lymphoma.
Some of the major companies that operate in the oncology segment in the North American region are adopting several strategies, such as collaboration and acquisition, to strengthen their positions in the T-cell lymphoma market. For instance, in August 2020, BostonGene Corporation announced the collaboration with The Weinstock Laboratory, which is at Dana-Farber Cancer Institute Inc. The collaboration is focused on defining predictors of response to PI3 kinase inhibition in relapsed/refractory T-cell lymphomas. In addition, other companies, such as Amgen and Merck, have been working on developing cancer therapies for T-cell lymphomas. Hence the aforementioned factors are expected to fuel market growth in this region.
T-Cell Lymphoma Market Competitor Analysis
The T-cell lymphoma market is highly competitive and consists of a few major players. Companies like Johnson & Johnson (Janssen Pharmaceuticals Inc.), Novartis AG, Bristol Myers Squibb Company, Merck & Co. Inc., and F. Hoffmann-La Roche Ltd hold a substantial share in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Lymphoma Cancer Incidence
4.2.2 Advancements in T-cell Lymphoma-specific Therapies
4.2.3 Risk of Lymphoma due to Autoimmune Disorders
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Adverse Side Effects of Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type of Lymphoma
5.1.1 Peripheral T-cell Lymphoma
5.1.1.1 Cutaneous T-cell Lymphoma
5.1.1.2 Anaplastic Large Cell Lymphoma
5.1.1.3 Angio-immuno-blastic T-cell Lymphoma
5.1.1.4 Other Types of Lymphoma
5.1.2 T-cell Lymphoblastic Lymphoma
5.2 By Type of Therapy
5.2.1 Radiotherapy
5.2.2 Chemotherapy
5.2.3 Immunotherapy
5.2.4 Stem Cell Transplantation
5.2.5 Other Types of Therapies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Mundipharma International
6.1.2 Bristol-Myers Squibb Company
6.1.3 Genmab AS
6.1.4 Johnson & Johnson (Janssen Pharmaceuticals Inc.)
6.1.5 Merck & Co. Inc.
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Novartis AG
6.1.8 Autolus Therapeutics PLC
6.1.9 Acrotech Biopharma
6.1.10 Macopharma
7 MARKET OPPORTUNITIES AND FUTURE TRENDS